Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole

Elizabet V Guimarães, Paula VP Guerra, Francisco J PennaDepartment of Pediatrics, Medical School, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilObjective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on proton pump inh...

Full description

Bibliographic Details
Main Authors: Elizabet V Guimarães, Paula VP Guerra, Francisco J Penna
Format: Article
Language:English
Published: Dove Medical Press 2010-10-01
Series:Therapeutics and Clinical Risk Management
Online Access:http://www.dovepress.com/management-of-gastroesophageal-reflux-disease-and-erosive-esophagitis--a5539
id doaj-29da44908ae14954a0663161183044ab
record_format Article
spelling doaj-29da44908ae14954a0663161183044ab2020-11-24T20:57:04ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2010-10-012010default531537Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazoleElizabet V GuimarãesPaula VP GuerraFrancisco J PennaElizabet V Guimarães, Paula VP Guerra, Francisco J PennaDepartment of Pediatrics, Medical School, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilObjective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on proton pump inhibitors (PPIs), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of PPIs observed in the treatment of GERD in children and adolescents.Sources: Electronic search of PubMed/Medline and Cochrane Collaboration databases, and of abstracts on DDW, NASPGHAN, and ESPGHAN. We focused on controlled and randomized studies published since 2000 and identified reviews that presented a consensual position, and directives published within the last 10 years.Main results: PPIs are considered better antisecretory agents than H2-receptor antagonists. Although all PPIs are similar, they are not identical in their pharmacologic properties. For example, the acid-suppressive effect of esomeprazole, the S-isomer of omeprazole, persists for more than 16 hours after administration of the morning dose. Therefore, it can control acidity after night meals better than a single dose of omeprazole. Moreover, the onset of the suppressive effect of esomeprazole is faster. It achieves acid inhibition faster than other PPIs.Conclusion: Currently, the mainstream treatment for GERD in children is a PPI. Although PPIs are safe drugs, effective in healing erosive esophagitis, and in relieving symptoms, studies with esomeprazole have shown that this drug has as powerful an ability to inhibit acid secretion as omeprazole. It also seems that some pharmacologic properties of esomeprazole are actually better for the treatment of GERD.Keywords: gastroesophageal reflux, therapy, child, adolescent. http://www.dovepress.com/management-of-gastroesophageal-reflux-disease-and-erosive-esophagitis--a5539
collection DOAJ
language English
format Article
sources DOAJ
author Elizabet V Guimarães
Paula VP Guerra
Francisco J Penna
spellingShingle Elizabet V Guimarães
Paula VP Guerra
Francisco J Penna
Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
Therapeutics and Clinical Risk Management
author_facet Elizabet V Guimarães
Paula VP Guerra
Francisco J Penna
author_sort Elizabet V Guimarães
title Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
title_short Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
title_full Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
title_fullStr Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
title_full_unstemmed Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
title_sort management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole
publisher Dove Medical Press
series Therapeutics and Clinical Risk Management
issn 1176-6336
1178-203X
publishDate 2010-10-01
description Elizabet V Guimarães, Paula VP Guerra, Francisco J PennaDepartment of Pediatrics, Medical School, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilObjective: To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on proton pump inhibitors (PPIs), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of PPIs observed in the treatment of GERD in children and adolescents.Sources: Electronic search of PubMed/Medline and Cochrane Collaboration databases, and of abstracts on DDW, NASPGHAN, and ESPGHAN. We focused on controlled and randomized studies published since 2000 and identified reviews that presented a consensual position, and directives published within the last 10 years.Main results: PPIs are considered better antisecretory agents than H2-receptor antagonists. Although all PPIs are similar, they are not identical in their pharmacologic properties. For example, the acid-suppressive effect of esomeprazole, the S-isomer of omeprazole, persists for more than 16 hours after administration of the morning dose. Therefore, it can control acidity after night meals better than a single dose of omeprazole. Moreover, the onset of the suppressive effect of esomeprazole is faster. It achieves acid inhibition faster than other PPIs.Conclusion: Currently, the mainstream treatment for GERD in children is a PPI. Although PPIs are safe drugs, effective in healing erosive esophagitis, and in relieving symptoms, studies with esomeprazole have shown that this drug has as powerful an ability to inhibit acid secretion as omeprazole. It also seems that some pharmacologic properties of esomeprazole are actually better for the treatment of GERD.Keywords: gastroesophageal reflux, therapy, child, adolescent.
url http://www.dovepress.com/management-of-gastroesophageal-reflux-disease-and-erosive-esophagitis--a5539
work_keys_str_mv AT elizabetvguimarampatildees managementofgastroesophagealrefluxdiseaseanderosiveesophagitisinpediatricpatientsfocusondelayedreleaseesomeprazole
AT paulavpguerra managementofgastroesophagealrefluxdiseaseanderosiveesophagitisinpediatricpatientsfocusondelayedreleaseesomeprazole
AT franciscojpenna managementofgastroesophagealrefluxdiseaseanderosiveesophagitisinpediatricpatientsfocusondelayedreleaseesomeprazole
_version_ 1716788863165267968